20 Participants Needed

Neurostimulation for Parkinson's Disease

Recruiting at 4 trial locations
DM
AS
Overseen ByAndrew Schnaubelt, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Nebraska
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop your current medications. However, it mentions that your motor symptoms should be severe enough despite optimized medical therapy, suggesting you may continue your current Parkinson's medications.

What data supports the effectiveness of the treatment Sub-clinical stimulation for Parkinson's Disease?

Research shows that electrical stimulation of the subthalamic nucleus can improve motor symptoms and quality of life in patients with advanced Parkinson's disease, suggesting it might be beneficial even at earlier stages of the disease.12345

Is neurostimulation for Parkinson's disease generally safe for humans?

Neurostimulation, specifically deep brain stimulation, has been used for Parkinson's disease, but it can have complications. About 25% of patients may experience issues, and 4-6% could have lasting neurological problems. It's important to understand these risks when considering this treatment.26789

How does sub-clinical stimulation differ from other treatments for Parkinson's disease?

Sub-clinical stimulation, a form of neurostimulation, is unique because it involves high-frequency electrical stimulation of the subthalamic nucleus, which can improve motor symptoms and emotional processing in Parkinson's disease by enhancing dopamine release and altering neuronal activity. This approach is different from traditional drug treatments like levodopa, which primarily focus on replacing dopamine.13101112

What is the purpose of this trial?

Parkinson's disease (PD) is a neurodegenerative disorder that leads to both motor and non-motor symptoms. Therapies have been developed that effectively target the motor symptoms. Non-motor symptoms are far more disabling for patients, precede the onset of motor symptoms by a decade, are more insidious in onset, have been less apparent to clinicians, and are less effectively treated. Sleep dysfunction is oftentimes the most burdensome of the non-motor symptoms. There are limited options for treating sleep dysfunction in PD, and the mainstay of therapy is the use of sedative-hypnotic drugs without addressing the underlying mechanisms. Patients with PD who demonstrate significant motor fluctuations and dyskinesia are considered for subthalamic nucleus (STN) deep brain stimulation (DBS) surgery. Several studies have reported that STN-DBS also provides benefit for sleep dysregulation. Additionally, local field potentials recorded from STN DBS electrodes implanted for the treatment of PD, have led to the identification of unique patterns in STN oscillatory activity that correlate with distinct sleep cycles, offering insight into sleep dysregulation. This proposal will leverage novel investigational DBS battery technology (RC+S Summit System; Medtronic) that allows the exploration of sleep biomarkers and prototyping of closed-loop stimulation algorithms, to test the hypothesis that STN contributes to the regulation and disruption of human sleep behavior and can be manipulated for therapeutic advantage. Specifically, in PD patients undergoing STN-DBS, the investigators will determine whether STN oscillations correlate with sleep stage transitions, then construct and evaluate sensing and adaptive stimulation paradigms that allow ongoing sleep-stage identification, and induce through adaptive stimulation an increase in duration of sleep stages associated with restorative sleep.

Research Team

Casey Halpern, M.D., Assistant ...

Casey Halpern, MD

Principal Investigator

Stanford University

CK

Clete Kushida, MD, PhD

Principal Investigator

Stanford University

JT

John Thompson, PhD

Principal Investigator

University of Colorado, Denver

AA

Aviva Abosch, MD, PhD

Principal Investigator

University of Nebraska

Eligibility Criteria

This trial is for adults aged 21-80 with Parkinson's Disease (PD) who have severe motor symptoms not adequately managed by medication, and are candidates for deep brain stimulation surgery. They must have had PD motor symptoms for at least 4 years, no significant cognitive deficits or depression, and no history of certain medical conditions like seizures or heart disease.

Inclusion Criteria

My Parkinson's symptoms improve by at least 30% with medication, or I have significant, treatment-resistant tremor.
Ability to provide informed consent for this study
My Parkinson's symptoms haven't improved with oral medications.
See 5 more

Exclusion Criteria

I have had brain surgery before.
Pre-existing implanted stimulation system (e.g., cochlear implant, cardiac pacemaker, defibrillator, neuro-stimulator for indication other than Parkinson's disease) or ferromagnetic metallic implant
I do not have uncontrolled blood pressure, bleeding disorders, seizures, heart disease, or issues with anesthesia.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Surgery and Initial Recovery

Participants undergo standard-of-care STN DBS lead implantation surgery for the treatment of PD

3 weeks
1 visit (in-person)

In-patient Sleep Lab

Participants return for 3 nights of STN LFP recordings with concurrent PSG, EMG, EOG, actigraphy, and video-EEG to establish a physiological sleep baseline and test sub-clinical stimulation

1 week
3 visits (in-patient)

Adaptive Stimulation Implementation

Implementation of adaptive stimulation algorithm developed in Aim 1 during nighttime sleep over 3 weeks of in-home sleep

3 weeks

Follow-up

Participants are monitored for safety and effectiveness after adaptive stimulation

4 weeks

Treatment Details

Interventions

  • Sub-clinical stimulation
Trial Overview The study tests if subthalamic nucleus oscillations can be linked to sleep stages in PD patients and whether adaptive neurostimulation can increase restorative sleep. It uses advanced DBS technology to identify sleep biomarkers and create stimulation patterns that adapt to ongoing sleep-stage changes.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PD with DBSExperimental Treatment1 Intervention
Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Nebraska

Lead Sponsor

Trials
563
Recruited
1,147,000+

Stanford University

Collaborator

Trials
2,527
Recruited
17,430,000+

University of Colorado, Denver

Collaborator

Trials
1,842
Recruited
3,028,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Findings from Research

Deep brain stimulation is an effective treatment for movement disorders, involving an implanted electrode and pulse generator, but its mechanisms of action are not fully understood and were developed without extensive preclinical safety studies.
Complication rates for deep brain stimulation can exceed 25%, with 4-6% of patients experiencing permanent neurological issues, highlighting the need for better understanding of adverse events and safer stimulation methods.
Safety considerations for deep brain stimulation: review and analysis.Grill, WM.[2007]
In a study of 233 Parkinson's Disease patients who underwent Deep Brain Stimulation (DBS) of the subthalamic nucleus, only 11.76% of procedures resulted in surgical adverse events (SAEs), indicating a relatively low risk associated with the procedure.
Most SAEs were reversible, with only two cases leading to long-term effects, demonstrating that STN DBS is a safe surgical option with a high reliability rate of 95.59% for correct lead implantation.
Surgical adverse events of deep brain stimulation in the subthalamic nucleus of patients with Parkinson's disease. The learning curve and the pitfalls.Seijo, F., Alvarez de Eulate Beramendi, S., Santamarta Liébana, E., et al.[2022]
Subthalamic nucleus deep brain stimulation (STN DBS) is an effective treatment for both younger (<65 years) and older (≥65 years) patients with Parkinson's disease, showing significant improvements in motor function and medication dosage after 6 months.
While STN DBS is generally safe, older patients experienced a higher rate of complications (11.8%) compared to younger patients (2.6%), suggesting that careful consideration is needed when selecting older patients for this procedure.
Bilateral subthalamic deep brain stimulation is an effective and safe treatment option for the older patients with Parkinson's disease.Kim, M., Cho, KR., Park, JH., et al.[2019]

References

Neurostimulation for Parkinson's disease with early motor complications. [2022]
A randomized trial of deep-brain stimulation for Parkinson's disease. [2023]
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. [2022]
Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study. [2016]
Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. [2022]
Safety considerations for deep brain stimulation: review and analysis. [2007]
Surgical adverse events of deep brain stimulation in the subthalamic nucleus of patients with Parkinson's disease. The learning curve and the pitfalls. [2022]
Bilateral subthalamic deep brain stimulation is an effective and safe treatment option for the older patients with Parkinson's disease. [2019]
Older Candidates for Subthalamic Deep Brain Stimulation in Parkinson's Disease Have a Higher Incidence of Psychiatric Serious Adverse Events. [2020]
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. [2019]
12.United Statespubmed.ncbi.nlm.nih.gov
Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security